ELGAN Pharma Awarded $2.5 Million EU Grant to Support Phase III Registrational Study of ELGN-GI for the Treatment of Intestinal Malabsorption in Preterm Infants July 19, 2023
Elgan Pharma Announces Positive Results from its Phase III Study of ELGN-GI in Preterm Infants for Treatment of Intestinal Malabsorption March 2, 2022
